Zimmer Biomet Holdings, Inc.

ZBH · NYSE

ZBH has an annual revenue baseline of $8.2B, latest revenue marker of $2.1B Q1 2026, annual net income of $705.1M and cash of $424.2M. The thesis depends on revenue durability, margins, cash conversion and balance-sheet discipline.

Follow Add to Watchlist Ask Question

NYSE ZBH Coverage Bootstrap Zimmer Biomet Holdings, Inc.

Latest ReportMay 20, 2026Zimmer Biomet: medtech durability still has to prove procedure demand, margin quality and cash conversionView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Company filters1 company reports

Add tags

Latest Thesis

Zimmer Biomet: medtech durability still has to prove procedure demand, margin quality and cash conversion

May 20, 2026Research reportSlides available

Read report Open slides Discussion (0)

Zimmer Biomet Holdings, Inc.Biomet: medtech durability still has to prove procedure demand, May 20, 2026

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Recent Reports

Compact report index for this company.

View all 1 reports ->

ReportTypeUpdatedReadActions

Zimmer Biomet: medtech durability still has to prove procedure demand, margin quality and cash conversionZBH has an annual revenue baseline of $8.2B, latest revenue marker of $2.1B Q1 2026, annual net income of $705.1M and cash of $424.2M. The thesis depends on revenue durability, margins, cash conversion and balance-sheet discipline.NYSEMay 20, 2026Research reportRead Slides